{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:01:45Z","timestamp":1788134505059,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"DFG","award":["KL 595\/2-3"],"award-info":[{"award-number":["KL 595\/2-3"]}]},{"name":"IZKF Promotionskolleg Universit\u00e4t T\u00fcbingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Res Cardiol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00395-019-0719-0","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T21:30:26Z","timestamp":1548365426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Blocking the IL-1\u03b2 signalling pathway prevents chronic viral myocarditis and cardiac remodeling"],"prefix":"10.1007","volume":"114","author":[{"given":"Lisa","family":"Kraft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugs","family":"Erdenesukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-2498","authenticated-orcid":false,"given":"Karin","family":"Klingel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"719_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.biopha.2018.08.004","volume":"107","author":"M Al-Kofahi","year":"2018","unstructured":"Al-Kofahi M, Omura S, Tsunoda I, Sato F, Becker F, Gavins FNE, Woolard MD, Pattillo C, Zawieja D, Muthuchamy M, Gashev A, Shihab I, Ghoweba M, Von der Weid PY, Wang Y, Alexander JS (2018) IL-1beta reduces cardiac lymphatic muscle contraction via COX-2 and PGE2 induction: Potential role in myocarditis. Biomed Pharmacother 107:1591\u20131600. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.004","journal-title":"Biomed Pharmacother"},{"key":"719_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.15252\/emmm.201708089","volume":"10","author":"N Althof","year":"2018","unstructured":"Althof N, Goetzke CC, Kespohl M, Voss K, Heuser A, Pinkert S, Kaya Z, Klingel K, Beling A (2018) The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Mol Med 10:200\u2013218. https:\/\/doi.org\/10.15252\/emmm.201708089","journal-title":"EMBO Mol Med"},{"key":"719_CR3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1161\/circresaha.109.213157","volume":"106","author":"GC Baldeviano","year":"2010","unstructured":"Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D (2010) Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 106:1646\u20131655. https:\/\/doi.org\/10.1161\/circresaha.109.213157","journal-title":"Circ Res"},{"key":"719_CR4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636\u20132648. https:\/\/doi.org\/10.1093\/eurheartj\/eht210","journal-title":"Eur Heart J"},{"key":"719_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fimmu.2017.00131","volume":"8","author":"G Cavalli","year":"2017","unstructured":"Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M (2017) Dagna L interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol 8:131. https:\/\/doi.org\/10.3389\/fimmu.2017.00131","journal-title":"Front Immunol"},{"key":"719_CR6","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/ccm.0000000000001654","volume":"44","author":"G Cavalli","year":"2016","unstructured":"Cavalli G, Pappalardo F, Mangieri A, Mangieri A, Dinarello CA, Dinarello CA, Dagna L, Dagna L, Tresoldi M (2016) Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med 44:e751\u2013e754. https:\/\/doi.org\/10.1097\/ccm.0000000000001654","journal-title":"Crit Care Med"},{"key":"719_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.carpath.2005.11.008","volume":"15","author":"C Cheung","year":"2006","unstructured":"Cheung C, Luo H, Yanagawa B, Leong HS, Samarasekera D, Lai JC, Suarez A, Zhang J, McManus BM (2006) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc Pathol 15:63\u201374. https:\/\/doi.org\/10.1016\/j.carpath.2005.11.008","journal-title":"Cardiovasc Pathol"},{"key":"719_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/j.1600-6143.2009.02706.x","volume":"9","author":"JA Diaz","year":"2009","unstructured":"Diaz JA, Booth AJ, Lu G, Wood SC, Pinsky DJ, Bishop DK (2009) Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 9:1773\u20131783. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02706.x","journal-title":"Am J Transplant"},{"key":"719_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519\u2013550. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132612","journal-title":"Annu Rev Immunol"},{"key":"719_CR10","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720\u20133732. https:\/\/doi.org\/10.1182\/blood-2010-07-273417","journal-title":"Blood"},{"key":"719_CR11","unstructured":"EMEA (2009) CHMP assessment report for Ilaris. London. https:\/\/www.ema.europa.eu\/documents\/assessment-report\/ilaris-epar-public-assessment-report_en.pdf . Accessed 23 July 2009"},{"key":"719_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11886-018-1007-6","volume":"20","author":"G Emmi","year":"2018","unstructured":"Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, Cantarini L, Prisco D, Brucato A (2018) Use of Interleukin-1 blockers in pericardial and cardiovascular diseases. Curr Cardiol Rep 20:61. https:\/\/doi.org\/10.1007\/s11886-018-1007-6","journal-title":"Curr Cardiol Rep"},{"key":"719_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1152\/physrev.00008.2011","volume":"92","author":"NG Frangogiannis","year":"2012","unstructured":"Frangogiannis NG (2012) Matricellular proteins in cardiac adaptation and disease. Physiol Rev 92:635\u2013688. https:\/\/doi.org\/10.1152\/physrev.00008.2011","journal-title":"Physiol Rev"},{"key":"719_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","volume":"30","author":"A Frustaci","year":"2009","unstructured":"Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30:1995\u20132002. https:\/\/doi.org\/10.1093\/eurheartj\/ehp249","journal-title":"Eur Heart J"},{"key":"719_CR15","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1128\/JVI.73.5.3587-3594.1999","volume":"73","author":"M Huber","year":"1999","unstructured":"Huber M, Watson KA, Selinka HC, Carthy CM, Klingel K, McManus BM, Kandolf R (1999) Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication. J Virol 73:3587\u20133594","journal-title":"J Virol"},{"key":"719_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/path.4369","volume":"234","author":"K Klingel","year":"2014","unstructured":"Klingel K, Fabritius C, Sauter M, Goldner K, Stauch D, Kandolf R, Ettischer N, Gahlen S, Schonberger T, Ebner S, Makrigiannis AP, Belanger S, Diefenbach A, Polic B, Pratschke J, Kotsch K (2014) The activating receptor NKG2D of natural killer cells promotes resistance against enterovirus-mediated inflammatory cardiomyopathy. J Pathol 234:164\u2013177. https:\/\/doi.org\/10.1002\/path.4369","journal-title":"J Pathol"},{"key":"719_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1073\/pnas.89.1.314","volume":"89","author":"K Klingel","year":"1992","unstructured":"Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R (1992) Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A 89:314\u2013318. https:\/\/doi.org\/10.1073\/pnas.89.1.314","journal-title":"Proc Natl Acad Sci U S A"},{"key":"719_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000073205","volume":"46","author":"GR Krueger","year":"2003","unstructured":"Krueger GR, Ablashi DV (2003) Human herpesvirus-6: a short review of its biological behavior. Intervirology 46:257\u2013269. https:\/\/doi.org\/10.1159\/000073205","journal-title":"Intervirology"},{"key":"719_CR19","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1161\/01.cir.0000072766.67150.51","volume":"107","author":"U Kuhl","year":"2003","unstructured":"Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793\u20132798. https:\/\/doi.org\/10.1161\/01.cir.0000072766.67150.51","journal-title":"Circulation"},{"key":"719_CR20","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1161\/circulationaha.105.548156","volume":"112","author":"U Kuhl","year":"2005","unstructured":"Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP (2005) Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112:1965\u20131970. https:\/\/doi.org\/10.1161\/circulationaha.105.548156","journal-title":"Circulation"},{"key":"719_CR21","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.4049\/jimmunol.151.3.1682","volume":"151","author":"JR Lane","year":"1993","unstructured":"Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR (1993) Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol 151:1682\u20131690","journal-title":"J Immunol"},{"key":"719_CR22","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1161\/01.CIR.0000012492.06971.88","volume":"105","author":"BK Lim","year":"2002","unstructured":"Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS, Kim S, Jeon ES (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105:1278\u20131281. https:\/\/doi.org\/10.1161\/01.CIR.0000012492.06971.88","journal-title":"Circulation"},{"key":"719_CR23","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1128\/JVI.76.7.3365-3373.2002","volume":"76","author":"H Luo","year":"2002","unstructured":"Luo H, Yanagawa B, Zhang J, Luo Z, Zhang M, Esfandiarei M, Carthy C, Wilson JE, Yang D, McManus BM (2002) Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 76:3365\u20133373. https:\/\/doi.org\/10.1128\/JVI.76.7.3365-3373.2002","journal-title":"J Virol"},{"key":"719_CR24","doi-asserted-by":"publisher","first-page":"e35144","DOI":"10.1371\/journal.pone.0035144","volume":"7","author":"F Ma","year":"2012","unstructured":"Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y, Du J (2012) Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF \u03b2\/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 7:e35144. https:\/\/doi.org\/10.1371\/journal.pone.0035144","journal-title":"PLoS One"},{"key":"719_CR25","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1161\/CIRCULATIONAHA.110.960054","volume":"121","author":"DJ Marchant","year":"2010","unstructured":"Marchant DJ, McManus BM (2010) Regulating viral myocarditis: allografted regulatory T cells decrease immune infiltration and viral load. Circulation 121:2609. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.960054","journal-title":"Circulation"},{"key":"719_CR26","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","volume":"113","author":"BJ Maron","year":"2006","unstructured":"Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies. Circulation 113:1807. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.174287","journal-title":"Circulation"},{"key":"719_CR27","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1089\/104303401750270940","volume":"12","author":"A Nakano","year":"2001","unstructured":"Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, Sasayama S, Miyazaki JI (2001) Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 12:1289\u20131297. https:\/\/doi.org\/10.1089\/104303401750270940","journal-title":"Hum Gene Ther"},{"key":"719_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1006\/clin.1993.1116","volume":"68","author":"DA Neumann","year":"1993","unstructured":"Neumann DA, Lane JR, Allen GS, Herskowitz A, Rose NR (1993) Viral myocarditis leading to cardiomyopathy: do cytokines contribute to pathogenesis? Clin Immunol Immunopathol 68:181\u2013190. https:\/\/doi.org\/10.1006\/clin.1993.1116","journal-title":"Clin Immunol Immunopathol"},{"key":"719_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cyto.2008.07.004","volume":"44","author":"O Osborn","year":"2008","unstructured":"Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T (2008) Treatment with an interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44:141\u2013148. https:\/\/doi.org\/10.1016\/j.cyto.2008.07.004","journal-title":"Cytokine"},{"key":"719_CR30","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701408r","author":"K Pappritz","year":"2018","unstructured":"Pappritz K, Savvatis K, Miteva K, Kerim B, Dong F, Fechner H, Muller I, Brandt C, Lopez B, Gonzalez A, Ravassa S, Klingel K, Diez J, Reinke P, Volk HD, Van Linthout S, Tschope C (2018) Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis. Faseb J. https:\/\/doi.org\/10.1096\/fj.201701408r","journal-title":"Faseb J"},{"key":"719_CR31","doi-asserted-by":"publisher","first-page":"e6656","DOI":"10.1097\/md.0000000000006656","volume":"24","author":"F Parisi","year":"2017","unstructured":"Parisi F, Paglionico A, Varriano V, Ferraccioli G, Gremese E (2017) Refractory adult-onset still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8\u00a0mg\/kg\/d) of anakinra. Med (Baltim) 24:e6656. https:\/\/doi.org\/10.1097\/md.0000000000006656","journal-title":"Med (Baltim)"},{"key":"719_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrcardio.2015.108","volume":"12","author":"A Pollack","year":"2015","unstructured":"Pollack A, Kontorovich AR, Fuster V, Dec GW (2015) Viral myocarditis\u2013diagnosis, treatment options, and current controversies. Nat Rev Cardiol 12:670\u2013680. https:\/\/doi.org\/10.1038\/nrcardio.2015.108","journal-title":"Nat Rev Cardiol"},{"key":"719_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"719_CR34","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/19420862.2015.1081323","volume":"7","author":"J-M Rondeau","year":"2015","unstructured":"Rondeau J-M, Ramage P, Zurini M, Gram H (2015) The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1\u03b2. MAbs 7:1151\u20131160. https:\/\/doi.org\/10.1080\/19420862.2015.1081323","journal-title":"MAbs"},{"key":"719_CR35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1161\/hypertensionaha.115.06004","volume":"66","author":"N Shimojo","year":"2015","unstructured":"Shimojo N, Hashizume R, Kanayama K, Hara M, Suzuki Y, Nishioka T, Hiroe M, Yoshida T, Imanaka-Yoshida K (2015) Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin alphaVbeta3\/nuclear factor-kappaB\/interleukin-6 axis. Hypertension 66:757\u2013766. https:\/\/doi.org\/10.1161\/hypertensionaha.115.06004","journal-title":"Hypertension"},{"key":"719_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","volume":"17","author":"MD Sternlicht","year":"2001","unstructured":"Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463\u2013516. https:\/\/doi.org\/10.1146\/annurev.cellbio.17.1.463","journal-title":"Annu Rev Cell Dev Biol"},{"key":"719_CR37","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1161\/circresaha.109.193805","volume":"104","author":"G Szalay","year":"2009","unstructured":"Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, Klingel K (2009) Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 104:851\u2013859. https:\/\/doi.org\/10.1161\/circresaha.109.193805","journal-title":"Circ Res"},{"key":"719_CR38","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.2353\/ajpath.2006.060350","volume":"169","author":"G Szalay","year":"2006","unstructured":"Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R, Klingel K (2006) Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol 169:2085\u20132093. https:\/\/doi.org\/10.2353\/ajpath.2006.060350","journal-title":"Am J Pathol"},{"key":"719_CR39","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S0735-1097(86)80349-7","volume":"7","author":"N Tomioka","year":"1986","unstructured":"Tomioka N, Kishimoto C, Matsumori A, Kawai C (1986) Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 7:868\u2013872. https:\/\/doi.org\/10.1016\/S0735-1097(86)80349-7","journal-title":"J Am Coll Cardiol"},{"key":"719_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/circheartfailure.117.003870","volume":"10","author":"C Tschope","year":"2017","unstructured":"Tschope C, Muller I, Xia Y, Savvatis K, Pappritz K, Pinkert S, Lassner D, Heimesaat MM, Spillmann F, Miteva K, Bereswill S, Schultheiss HP, Fechner H, Pieske B, Kuhl U, Van Linthout S (2017) NOD2 (nucleotide-binding oligomerization domain 2) is a major pathogenic mediator of Coxsackievirus B3-induced myocarditis. Circ Heart Fail 10:12. https:\/\/doi.org\/10.1161\/circheartfailure.117.003870","journal-title":"Circ Heart Fail"},{"key":"719_CR41","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1136\/hrt.2004.035733","volume":"91","author":"M Vanderheyden","year":"2005","unstructured":"Vanderheyden M, Paulus WJ, Voss M, Knuefermann P, Sivasubramanian N, Mann D, Baumgarten G (2005) Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 91:926\u2013931. https:\/\/doi.org\/10.1136\/hrt.2004.035733","journal-title":"Heart"},{"key":"719_CR42","doi-asserted-by":"publisher","first-page":"cm1","DOI":"10.1126\/scisignal.3105cm1","volume":"3","author":"A Weber","year":"2010","unstructured":"Weber A, Wasiliew P, Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 3:cm1. https:\/\/doi.org\/10.1126\/scisignal.3105cm1","journal-title":"Sci Signal"},{"key":"719_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jjcc.2013.09.013","volume":"63","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, Shao Y, Ma W, Yang D, Zhang J (2014) Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts. J Cardiol 63:373\u2013378. https:\/\/doi.org\/10.1016\/j.jjcc.2013.09.013","journal-title":"J Cardiol"}],"container-title":["Basic Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-019-0719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00395-019-0719-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-019-0719-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T04:52:26Z","timestamp":1694580746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00395-019-0719-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s00395-019-0719-0","relation":{},"ISSN":["0300-8428","1435-1803"],"issn-type":[{"value":"0300-8428","type":"print"},{"value":"1435-1803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"26 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KK received the IL-1\u03b2 antibody as a gift and research funding from Novartis AG. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"11"}}